Literature DB >> 9655356

Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis?

B Hoppe1, A Hesse, S Brömme, E Rietschel, D Michalk.   

Abstract

Patients with cystic fibrosis (CF) have an increased risk of urolithiasis/nephrocalcinosis. To determine potential mechanisms responsible, we studied the urinary excretion of lithogenic and stone-inhibitory substances and calculated the urinary saturation for calcium-oxalate (CaOx), brushite (CaHPO4), and uric acid (UA). We examined 24-h urines in 63 patients with CF (34 female, 29 male) aged 5 months to 36 years. Renal ultrasonography was performed at the time of urine collection. Hyperoxaluria was found in 25 patients (range 0.51-1.71 mmol/1.73 m2 per 24 h). Urinary Ca was increased in 13 patients (4.1-8.22 mg/kg per 24 h). Hyperuricosuria was found in 16 patients (5.2-18.0 mmol/1.73 m2 per 24 h) and hypocitraturia in 14 patients (0.07-1.14 mmol/1.73 m2 per 24 h). CaOx saturation was elevated in 26 patients, related to hyperoxaluria in 19 patients. CaHPO4 saturation was increased in 19 patients and UA saturation in 11 patients. Urolithiasis in situ was diagnosed in 1 patient; 3 patients previously had renal stones; 4 patients had present nephrocalcinosis. Elevated excretion of lithogenic substances and urinary supersaturation might lead to the higher risk of urolithiasis/nephrocalcinosis in patients with CF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655356     DOI: 10.1007/s004670050452

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

Review 1.  Primary and secondary hyperoxaluria: Understanding the enigma.

Authors:  Bhavna Bhasin; Hatice Melda Ürekli; Mohamed G Atta
Journal:  World J Nephrol       Date:  2015-05-06

Review 2.  Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?

Authors:  Bernd Hoppe; Gerd von Unruh; Norbert Laube; Albrecht Hesse; Harmeet Sidhu
Journal:  Urol Res       Date:  2005-11-13

Review 3.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

4.  Renal diseases in adults with cystic fibrosis: a 40 year single centre experience.

Authors:  M J Wilcock; A Ruddick; K M Gyi; M E Hodson
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

Review 5.  Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Authors:  Ammon B Peck; Benjamin K Canales; Cuong Q Nguyen
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

6.  Predisposing factors for nephrolithiasis and nephrocalcinosis in cystic fibrosis.

Authors:  Hamid-Reza Kianifar; Saeedeh Talebi; Mahmoodreza Khazaei; Saeed Talebi; Ali Alamdaran; Simin Hiradfar
Journal:  Iran J Pediatr       Date:  2011-03       Impact factor: 0.364

Review 7.  Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management.

Authors:  Dhiren Patel; Albert Shan; Stacy Mathews; Meghana Sathe
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

8.  Cystic fibrosis and renal disease: a case report.

Authors:  Baha A Al-Shawwa; Aparna R Rao
Journal:  J Med Case Rep       Date:  2007-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.